Chemours Company (CC) shares plunged 9.90% in pre-market trading, continuing the negative momentum from the previous session's after-hours decline.

The sharp drop follows the chemical company's release of disappointing fourth-quarter and full-year 2025 financial results that significantly missed analyst expectations. The company reported weaker-than-expected performance across key metrics, including earnings per share and revenue.

Chemours' Q4 adjusted earnings per share of $0.05 fell short of the consensus estimate of $0.07, while quarterly sales of $1.300 billion also missed expectations. More concerning to investors was the widening of the net loss attributable to shareholders to $47 million, a substantial increase from the $11 million loss reported a year earlier. The company attributed the poor performance to volume declines in its titanium technologies and advanced performance materials businesses due to weaker cyclically-sensitive end markets.